FinnGen Study

FinnGen biobank Study: launched 2017

A unique collaboration between academia and industry aiming to identify genotype-phenotype correlations in the Finnish founder population.

FinnGen has 4 main aims:

  1. 1.    Produce medical innovations by combining health registry and genome data
  2. 2.    Support Finland to become a pioneer in biomedicine and personalised healthcare
  3. 3.    Create a cooperation model between public sector and healthcare industry
  4. 4.    Provide early access to new personalised treatments and health innovations across Finland (and beyond)

The data will deepen our understanding about disease origins and their treatment and help prioritise drug targets based on genomic information. Ambitious project goals will help facilitate more efficient drug development pipelines and better individualised drug treatment choices

The project aims to produce close to complete genome variant data of 500,000 biobank participants using GWAS (genome-wide associated studies) genotyping. Currently, over 262,000 people have donated samples.

FINBB is part of the FinnGen ecosystem by facilitating the set-up and conduct of biobank studies ‘spinning off’ FinnGen – driven by academic or industry researchers.

FinnGen also aims to open new possibilities for domestic biotechnology companies and the Finnish business environment. More detailed information can be found here

The data will deepen our understanding about disease origins and their treatment and help prioritise drug targets based on genomic information. Ambitious project goals will help facilitate more efficient drug development pipelines and better individualised drug treatment choices.

bottomofpage